Crohn's Disease
Anti-TNF therapy significantly improves growth disturbances in pediatric Crohn’s
LAS VEGAS — Although a substantial proportion of children with Crohn’s disease had growth disturbances at initiation of anti-tumor necrosis factor therapy, “significant improvement” was noted up to 24 months after treatment, data showed.
VIDEO: ‘Presentation really matters’ when advising patients to work with IBD dietitian
LAS VEGAS — In a Healio video exclusive, Stacey Collins, MA, RDN/LD, highlights the importance of working with dietitians who specialize in inflammatory bowel disease and underscores their role on a patient’s care team.
The average cost of inflammatory bowel disease care neared $16,000 per patient in 2019
LAS VEGAS — The cost associated with treating inflammatory bowel disease “significantly increased” from 2009 to 2019 and was largely attributed to the annual cost of biologics, a presenter reported at the Crohn’s & Colitis Congress.
‘Perianal fistulas are preventable’ in pediatric Crohn’s with early anti-TNF therapy
LAS VEGAS — Early treatment with tumor necrosis antagonist was linked to 79% reduced odds of patients with pediatric Crohn’s disease developing perianal fistulizing complications, noted a presenter at the Crohn’s & Colitis Congress.
Growing armamentarium of therapies for IBD has ‘truly revolutionized’ care
LAS VEGAS —A presenter at the Crohn’s & Colitis Congress outlined some of the newer therapies that have expanded the current “arsenal of tools” for the treatment of inflammatory bowel disease.
Atopic dermatitis may be linked to inflammatory bowel disease
An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.
Q&A: Zymfentra ‘gives patients an option’ for at-home maintenance therapy of IBD
The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.
Foreign-born patients with IBD have ‘milder’ disease, later onset, regardless of race
Inflammatory bowel disease phenotype and behavior vary by race and immigration status, with foreign-born patients of all races experiencing less severe disease and later onset than those born in the U.S., researchers reported.
Biologics have only ‘slight impact’ vs. conventional therapy on surgery-free survival in CD
The introduction of biologics as a therapeutic option for Crohn’s disease had “only a slight impact” on eventual surgery occurrence, although it may delay the first intestinal resection compared with conventional therapy, data showed.
FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals
In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.